Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Delayed Quote USD

Aditxt, Inc. (ADTX)

Compare
4.5200
+0.0350
+(0.78%)
At close: 4:00:01 PM EDT
4.4600
-0.06
(-1.33%)
After hours: 4:41:26 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ADTX

Recent News: ADTX

View More

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
Business Wire 4 days ago
Evofem Reports Fourth Consecutive Year of Net Sales Growth

Evofem Reports Fourth Consecutive Year of Net Sales Growth
PR Newswire 8 days ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
Business Wire 8 days ago
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
GlobeNewswire 14 days ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025
Business Wire 15 days ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025
Business Wire 20 days ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.
Business Wire 26 days ago
Aditxt subsidiary Persanta engages Dominary Securities for IPO

Aditxt subsidiary Persanta engages Dominary Securities for IPO
TipRanks last month

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025
Business Wire last month

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time
Business Wire last month

Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform
Business Wire 2 months ago
View More

Related Tickers

RNAZ TransCode Therapeutics, Inc.
0.5409
+9.27%
 
IBO Impact BioMedical Inc.
0.8200
-5.75%
 
WINT Windtree Therapeutics, Inc.
1.2000
-4.76%
 
OCEA Ocean Biomedical, Inc.
0.0549
+1.67%
 
PSTV Plus Therapeutics, Inc.
1.0200
+7.36%
 
CRVO CervoMed Inc.
9.98
+9.07%
 
HEPA Hepion Pharmaceuticals, Inc.
0.4850
+12.82%
 
CDT Conduit Pharmaceuticals Inc.
0.7221
-7.54%
 
DRMA Dermata Therapeutics, Inc.
0.9997
-7.44%
 
OSRH OSR Holdings, Inc.
1.7200
-8.51%